EFFECTS OF CYP2C19 AND P2Y12 GENE POLYMORPHISMS
ON CLINICAL RESULTS OF PATIENTS USING CLOPIDOGREL
AFTER ACUTE ISCHEMIC CEREBROVASCULAR DISEASE
Sen HM1,*, Silan F2, Silan C3, Degirmenci Y4, Ozisik Kamaran HI1
*Corresponding Author: Halil Murat Sen, M.D., Department of Neurology, School of Medicine, Çanakkale Onsekiz
Mart Üniversity, Barboros Mah., Terzioðlu Kampüsü, Týp Fakültesi, Çanakkale, Turkey. Tel : +90-286-218-37-38.
Fax : +90-286-218-00-18. E-mail: hmuratsen@gmail.com
page: 37
|
|
REFERENCES
1. Adams RJ, Albers G, Alberts MJ, Benavente O,
Furie K, Goldstein LB, et al.; American Heart
Association; American Stroke Association. Update
to the AHA/ ASA recommendations for the
prevention of stroke in patients with stroke and
transient ischemic attack. Stroke. 2008; 39(5):
1647-1652.
2. Mukherjee D, Patil CG. Epidemiology and the
global burden of stroke. World Neurosurg. 2011;
76(6 Suppl): S85-S90.
3. Tousoulis D, Siasos G, Zaromitidou M, Oikonomou
E, Maniatis K, Kioufis S, et al. The impact
of CYP2C19 genotype on cardiovascular events
and platelet reactivity in patients with coronary
artery disease receiving clopidogrel. Int J Cardiol.
2013; 168(2): 1594-1596.
4. Heitzer T, Rudolph V, Schwedhelm E, Karstens
M, Sydow K, Ortak M, et al. Clopidogrel improves
systemic endothelial nitric oxide bioavailability
in patients with coronary artery disease:
evidence for antioxidant and antiinflammatory
effects. Arterioscler Thromb Vasc Biol. 2006;
26(7): 1648-1652
5. Chae H, Kim M, Koh YS, Hwang BH, Kang
MK, Kim Y, et al. Feasibility of a microarraybased
point-of-care CYP2C19 genotyping test
for predicting clopidogrel on-treatment platelet
reactivity. Biomed Res Int. 2013; 2013: 154073.
doi: 10.1155/2013/154073.
6. PharmGKB [Internet]. Palo Alto (CA): Stanford
University. Gene: CYP2C19. Available from:
http://www. pharmgkb.org/ gene/PA124. Accessed
November 10 2014.
7. Scott SA, Sangkuhl K, Gardner EE, Stein CM.
Clinical pharmacogenetics implementation consortium
guidelines for cytochrome P450-2C19
(CYP2C19) genotype and clopidogrel therapy.
Clin Parmacol Therapeut. 2011; 90(2): 328-332.
8. Kaikita K, Ono T, Iwashita S, Nakayama N, Sato
K, Horio E, et al. Impact of CYP2C19 polymorphism
on platelet function tests and coagulation
and inflammatory biomarkers in patients
undergoing percutaneous coronary intervention.
J Atheroscler Thromb. 2014; 21(1): 64-76.
9. Kim KA, Song WG, Lee HM, Joo HJ, Park JY.
Effect of P2Y1 and P2Y12 genetic polymorphisms
on the ADP-induced platelet aggregation
in a Korean population. Thromb Res. 2013;
132(2): 221-226.
10. Savi P, Pereillo JM, Uzabiaga MF, Combalbert
J, Picard C, Maffrand JP, et al. Identification
and biological activity of the active metabolite
of clopidogrel. Thromb Haemost. 2000; 84(5):
891-896.
11. Savi P, Laplace MC, Maffrand JP, Herbert JM.
Binding of [3H]-2methylthio ADP to rat platelets
– Effect of clopidogrel and ticlopidine. J
Pharmacol Exp Ther. 1994; 269(2): 772-777.
12. Feng D, Lindpaintner K, Larson MG, Rao
VS, O’Donnell CJ, Lipinska I, et al. Increased
platelet aggregability associated with platelet
GPIIIa PlA2 polymorphism: The Framingham
Offspring Study. Arterioscler Thromb Vasc Biol.
1999; 19(4): 1142-1147.
13. Lordkipanidze M, Diodati JG, Palisaitis DA,
Schampaert E, Turgeon J, Pharand C. Genetic
determinants of response to aspirin: Appraisal of
4 candidate genes. Thromb Res. 2011; 128(1):
47-53
14. Ziegler S, Schillinger M, Funk M, Felber K,
Exner M, Mlekusch W, et al. Association of
a functional polymorphism in the clopidogrel
target receptor gene, P2Y12, and the risk for
ischemic cerebrovascular events in patients with
peripheral artery disease. Stroke. 2005; 36(7):
1394-1399.
15. Mao L, Jian C, Changzhi L, Dan H, Suihua H,
Wenyi T, et al. Cytochrome CYP2C19 polymorphism
and risk of adverse clinical events
in clopidogrel-treated patients: A meta-analysis
based on 23,035 subjects. Arch Cardiovasc Dis.
2013; 106(10): 517-527.
16. Tang XF, Zhang JH, Wang J, Han YL, Xu B,
Qiao SB, et al. Effects of coexisting polymorphisms
of CYP2 C19 and P2Y12 on clopidogrel
responsiveness and clinical outcome in patients
with acute coronary syndromes undergoing
stent-based coronary intervention. Chin Med J
(Engl). 2013; 126(6): 1069-1075.
17. CAPRIE Steering Committee. A randomized,
blinded, trial of clopidogrel versus aspirin in
patients at risk for ischemic events (CAPRIE).
Lancet. 1996; 348 (9038): 1329-1339.
18. Gurbel PA, Bliden KP. Durability of platelet
inhibition by clopidogrel. Am J Cardiol. 2003;
91(9): 1123-1125.
19. Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM.
Clopidogrel for coronary stenting: response variability,
drug resistance, and the effect of pretreatment
platelet reactivity. Circulation. 2003;
107(23): 2908-2913.
20. Spokoyny I, Barazangi N, Jaramillo V, Rose J,
Chen C, Wong C, et al. Reduced clopidogrel metabolism
in a multiethnic population: Prevalence
and rates of recurrent cerebrovascular events. J
Stroke Cerebrovasc Dis. 2014; 23(4): 694-698.
21. Anderson CD, Biffi A, Greenberg SM, Rosand J.
Personalized approaches to clopidogrel therapy:
Are we there yet? Stroke. 2010; 41(12): 2997-3002.
22. US Food and Drug Administration. Clopidogrel
black box warning. Available from: http://
www.fda.gov/ drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/
ucm203888.htm. Accessed November 10, 2014.
23. Terpening C. Clopidogrel: A pharmacogenomic
perspective on its use in coronary artery disease.
Clin Med Insights Cardiol. 2010; 4(1): 117-128.
|
|
|
|
 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
|
